# Table of Contents

## Editorial
- 3

## Mission
- 5

## Science & dissemination
- 6
  - MEETINGS
    - 1. ESTRO 2023 7
    - 2. Joint & collaboration events 12
    - 3. ESTRO workshops 16
  - PUBLICATIONS
    - 1. The Green Journal 19
    - 2. Open access journals 22
  - RESEARCH & DISSEMINATION 30
  - GUIDELINES 33

## ESTRO School
- 34
  - 1. 2023 ESTRO School Activities at a glance 36
  - 2. Teaching courses 37
  - 3. E-Learning 41

## Membership & partnerships
- 44
  - 1. Profile of ESTRO members 45
  - 2. A wide range of membership categories 46
  - 3. Membership categories under the spotlight 48
  - RTT Alliance 52
  - MoUs 52

## ESTRO Cancer Foundation (ECF)
- 53

## Financial report
- 55
  - 1. Treasurer’s report for 2023 56
  - 2. ESTRO audited accounts 2022 57
  - 3. Cumulative result 2008-2023 58

## Annex
- 59
  - 1. Governance & constituent bodies 60
  - 2. Staff 62
  - 3. Corporate members 62
  - 4. Joint members 63
  - 5. RTT Alliance 63
  - 6. Institutional members 64
  - 7. Radiotherapy and Oncology and open access journals 65
  - 8. Awards 67
  - 9. Newsletter 67
  - 10. Endorsed events in 2023 68

## Financial report
- 55
  - 1. Treasurer’s report for 2023 56
  - 2. ESTRO audited accounts 2022 57
  - 3. Cumulative result 2008-2023 58

## Annex
- 59
  - 1. Governance & constituent bodies 60
  - 2. Staff 62
  - 3. Corporate members 62
  - 4. Joint members 63
  - 5. RTT Alliance 63
  - 6. Institutional members 64
  - 7. Radiotherapy and Oncology and open access journals 65
  - 8. Awards 67
  - 9. Newsletter 67
  - 10. Endorsed events in 2023 68
2023 was a year of extraordinary growth for ESTRO, both for its community and its outputs.

With 6,722 participants, ESTRO 2023 was the largest annual congress in the history of our Society. Held in Vienna, Austria, this major milestone marked the culmination of the restoration of the many ESTRO activities and events that had been temporarily paused by the global pandemic. Reaching such a milestone so rapidly after a black swan event simply would have not been possible without the unwavering support and trust of our community, not least the ESTRO 2023 scientific programme committee which put together content and speakers truly worthy of the congress theme: “From Innovation to Action”.

2023 also saw ESTRO’s membership surge beyond 9,000 for the first time. This remarkable growth in our membership reflects a renewed enthusiasm among professionals in the radiation oncology community to be part of an interdisciplinary Society whose members work together collaboratively to create outputs that are worth more than the sum of their parts. In parallel, ESTRO’s new governance structure with its increased openness and transparency enables the Society to listen more effectively, to respond to its community’s needs, and to adjust its offerings accordingly.

In terms of the nature of ESTRO membership, individual membership remained the largest segment in 2023, representing 54% of the total number of members. The institutional membership has served as a steady foundation for the Society, demonstrating high retention rates and contributing significantly to our pool of full members. Furthermore, the increasing number of Memoranda of Understanding between ESTRO and national societies highlights the growing potential of joint memberships for the Society. The distribution of membership remains relatively stable: approximately half of the ESTRO membership is clinicians, a fifth medical physicists, and just over 1 in 10 radiation therapists. ESTRO is working to expand its radiation biology community and to embrace other radiation-research-related specialties not currently formally represented within our structure. Demographic trends indicate growth in the number of young members, with around 45% of the membership being 40 years or younger. The strengthened interest in joining the Society not only underscores the relevance of ESTRO’s initiatives but also positions ESTRO membership as an integral part of a radiation oncology professional’s identity. Meanwhile, the diverse composition of ESTRO’s membership, drawing
from various global locations, age groups, and disciplines, highlights the Society’s commitment to fostering a dynamic and inclusive professional community.

Building on ESTRO’s new governance model, approved in 2022, the Society in 2023 continued to grow its reach by consolidating the work of the Professions and Partnerships Council through the inauguration of the first wave of ESTRO focus groups. These cover a wide array of tumour sites and treatment techniques and are expected to amplify the Society’s output across multiple areas of interest. Sixteen focus groups were launched and attracted nearly 300 volunteers from the ESTRO community. A dedicated effort was made to engage younger colleagues, and this move resulted in an enthusiastic response from the community.

Having embedded its organisational framework, the ESTRO leadership turned its attention to a re-evaluation of its strategy towards achieving the 2030 Vision during a two-day strategy retreat held in Brussels, Belgium. This gathering, which involved the Board of Directors and chairs of all ESTRO committees, was the first of its kind in five years since the 2018 retreat in Mechelen, Belgium. That retreat led to the publication of the ESTRO 2030 Vision statement. This strategy retreat reaffirmed the 2030 Vision ‘Radiation Oncology, Optimal Health, For All, Together’ and identified key strategic objectives for the 2024-26 period. These objectives were aimed to optimise content alongside networking opportunities, to continue to grow our Society and to work towards diversifying its outputs. Strategic objectives have now been entrusted to the ESTRO councils for implementation.

In terms of 2023 ESTRO events beyond the congress, the popularity of ESTRO workshops soared once again, with the physics workshop in Turin, Italy, and the GEC-ESTRO workshop in Prague, Czech Republic, reaching attendances of 153 and 229 delegates respectively. Meanwhile, the ESTRO School, renowned for its rich variety of educational offerings, reached an impressive 3,993 attendees. Additional teaching formats such as hybrid courses and on-demand content have been successfully expanded, allowing the Society to extend its global educational reach.

The Science Unit also continued to broaden its activities. The ESTRO guidelines committee expanded the number of its sub-groups working on different initiatives, which culminated in the publication of 12 guidelines in 2023. In the frame of the Scientific Engagement Policy, ESTRO continued to support research relevant to radiotherapy and actively took part in several EU-funded projects. The collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) on the EORTC-ESTRO radiotherapy infrastructure for Europe (E2-RADlatE) project continued and the European Particle Therapy Network grew in terms of the number of activities and outreach. Outputs from the ESTRO family of journals increased in 2023, with ctRO maintaining a strong impact factor and phiRO obtaining its first.

In summary, 2023 was a remarkably fruitful year for ESTRO. The Society was reinvigorated by the introduction of a more inclusive and transparent governance structure. It reaped the benefits of its capacity to adapt in the face of adversity and claimed the full spectrum of its activities. This transformative journey was underpinned by a renewed sense of community and a commitment of all the disciplines represented in the ESTRO family to a common goal: the delivery of the highest quality radiation therapy for our patients through the dissemination of excellent science, promotion of networking and fostering of interdisciplinary collaboration. Huge thanks to all our members for their energy and commitment and we look forward to working with you all throughout 2024 to strengthen our voice and our impact in global cancer care.

Anna Kirby
ESTRO President
Mission

The mission of ESTRO, a non-profit, scientific organisation, shall be to foster, in all its aspects, radiotherapy (also known as radiation oncology), clinical oncology and related subjects, including physics as applied to radiotherapy, radiation technology and radiobiology.

To fulfil its mission ESTRO will:

- Develop and promote standards of education in radiotherapy and clinical oncology
- Promote standards of practice in radiotherapy, clinical oncology and related subjects
- Stimulate the exchange of scientific knowledge in all related fields
- Strengthen the clinical speciality of radiotherapy and clinical oncology in relation to other specialities and professions involved in cancer management
- Encourage co-operation with international, regional and national societies and bodies representing radiotherapy, clinical oncology and related subjects
- Facilitate research and development in radiotherapy, clinical oncology and related subjects.
ESTRO has a long track record of organising conferences, disseminating the latest findings and providing a platform for networking hence working towards an optimal treatment care for cancer patients.
MEETINGS

1. ESTRO 2023

ESTRO 2023 covered the full spectrum of radiation oncology topics with up to 12 programme tracks, reflecting the highly-specialised disciplines in the field:

- Clinical
- Brachytherapy
- Physics
- RTT (Radiation Therapists)
- Radiobiology
- Young.

An “in real life” format
The entire programme was presented onsite. While the sessions weren’t live-streamed, they were recorded and made available as webcasts within a short time. This allowed delegates to catch-up on sessions they may have missed and experience more of the programme.

A top-level scientific programme
The latest science in radiation oncology was delivered via symposia, teaching lectures, debates, pitch sessions and panel discussions as well as proffered papers.

Interactive presentation formats
The highly-interactive mini-oral and poster discussion sessions, that proved so popular in 2022, were expanded giving more visibility to submitted work and research.

Young programme
A programme for young delegates was delivered on a dedicated day to provide those in the early stages of their career with the information and tools to make the most of their professional opportunities.

Many educational activities
In addition to the main scientific programme, several pre-meeting courses and contouring workshops were held. These are discussed in the School section of this report.

The Annual Congress of the European Society for Radiotherapy and Oncology
12-16 May 2023 | Vienna, Austria
For the first time, the ESTRO congress featured "Go Green" sessions held concurrently, addressing sustainability in radiotherapy. The agenda included insightful sessions such as an introduction to climate change and healthcare, discussions on carbon footprint and radiotherapy, a climate quiz, and updates on green initiatives in the USA. International speakers delivered lectures in a specially constructed small auditorium within the exhibition area.

This innovative initiative underscores ESTRO's commitment to advancing environmentally friendly practices. Notably, the congress embraced a paperless approach, with no abstract books (for now several years), programme overviews, or leaflets available at the ESTRO booth. Instead, participants accessed information through the ESTRO mobile app and the online platform, aligning with ESTRO's dedication to eco-conscious event management.
Science & Dissemination

EXHIBITION

110 Exhibitors

- Exhibitors: 96
- Start-ups: 2
- Community Pavilion: 12 national societies

2,502 Abstracts
1,299 Posters

327 Chairs
199 Sessions

296 Invited Speakers

4,930 Sqm
PARTICIPATION

6,722 Participants

- 79% Delegates
- 21% Company Representatives

Top 10 countries

- The Netherlands: 476
- UK: 457
- Germany: 334
- Italy: 315
- France: 247
- USA: 227
- Spain: 204
- Switzerland: 196
- Belgium: 194
- Denmark: 163

Most Represented Specialities

- 42.63% Radiation Oncologists
- 27.10% Medical Physicists
- 13.27% RTTs (Therapists), RT Nurses
- 9.19% Clinical Oncologists
- 1.61% Biologists
- 1.49% Dosimetrists
- 0.98% Computer Scientists
- 0.46% Medical Oncologists
- 0.15% Quality Managers
- 3.13% Other
Evolution of participation to the ESTRO Annual Conference 2015 - 2023

<table>
<thead>
<tr>
<th>Year</th>
<th>Delegates Only</th>
<th>Online Delegates Only</th>
<th>Total Online</th>
<th>Total Onsite</th>
<th>Total Delegates</th>
<th>Total Company Representatives</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESTRO 35</td>
<td>1,219</td>
<td>4,065</td>
<td>5,284</td>
<td>1,527</td>
<td>6,811</td>
<td>1,431</td>
</tr>
<tr>
<td>ESTRO 36</td>
<td>1,527</td>
<td>4,333</td>
<td>5,860</td>
<td>1,355</td>
<td>7,215</td>
<td>1,882</td>
</tr>
<tr>
<td>ESTRO 37</td>
<td>4,856</td>
<td>5,107</td>
<td>6,211</td>
<td>1,526</td>
<td>7,737</td>
<td>2,408</td>
</tr>
<tr>
<td>ESTRO 38</td>
<td>3,708</td>
<td>3,794</td>
<td>5,663</td>
<td>1,869</td>
<td>7,532</td>
<td>2,057</td>
</tr>
<tr>
<td>ESTRO 2020</td>
<td>2,372</td>
<td>2,372</td>
<td>5,104</td>
<td>1,527</td>
<td>6,631</td>
<td>1,437</td>
</tr>
<tr>
<td>ESTRO 2021</td>
<td>3,047</td>
<td>3,047</td>
<td>5,663</td>
<td>1,869</td>
<td>7,532</td>
<td>2,057</td>
</tr>
<tr>
<td>ESTRO 2022</td>
<td>3,794</td>
<td>3,794</td>
<td>6,722</td>
<td>1,417</td>
<td>8,139</td>
<td>2,036</td>
</tr>
<tr>
<td>ESTRO 2023</td>
<td>5,097</td>
<td>5,097</td>
<td>10,633</td>
<td>2,529</td>
<td>13,162</td>
<td>3,062</td>
</tr>
</tbody>
</table>

Delegates
Company Representatives
2. Joint and collaboration events 2023

2.2 European Lung Cancer Conference (ELCC 2023)
29 March - 1 April 2023 | Copenhagen, Denmark and Online

Organised by ESMO (European Society for Medical Oncology) and IASLC (International Association for the Study of Lung Cancer), in partnership with ESTRO, European Society of Thoracic Surgeons (ESTS) and the ETOP IBCSG Partners Foundation.

ELCC is a collaboration of the most important multidisciplinary societies that represent thoracic oncology specialists, working together to advance science, disseminate education and improve the practice of lung-cancer specialists worldwide.

Medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians/pneumologists, interventional radiologists and pathologists all benefit from its comprehensive programme.

3,056 Participants
111 Countries represented

Breakdown of participants:
- 89.4% Delegates
- 4.1% Faculty
- 4.1% Industry
- 2.5% Press
431 Abstracts submitted

- 222 accepted (51%)
- 209 rejected or withdrawn (49%)

Breakdown of participants

- 55% Onsite participants
- 45% Online participants
- 52% Female
- 48% Male

Average
42 years old

Breakdown per speciality

- 83.1% Oncology Clinicians (including 6.8% Radiation Oncologists)
- 8.9% Basic scientists
- 3.9% Pharmacists
- 1.9% Other healthcare professionals
- 2.2% Other (nurse, medical student, statistician, patient advocate, science student)

Top 10 countries

- USA: 9.2%
- Switzerland: 6.5%
- Spain: 6.2%
- India: 5%
- UK: 4.4%
- Romania: 4.4%
- The Netherlands: 3.4%
- Denmark: 3.3%
- Brazil: 3.2%
- Germany: 2.8%
- Belgium: 2.8%
2.3 European Multidisciplinary Congress on Urological Cancers (EMUC 2023)

Working together to improve patient care
2-5 November 2023 | Marseille, France - Jointly organised by EAU, ESMO and ESTRO

The 15th European Multidisciplinary Congress on Urological Cancers (EMUC23) placed a specific emphasis on the importance of multi-sectoral approach in the treatment of genitourinary (GU) malignancies.

The EMUC23 scientific programme highlighted the most recent developments in the prevention, diagnosis and best practices in the management of GU cancers.

Top 10 countries

- The Netherlands: 102
- Spain: 101
- Italy: 75
- Portugal: 75
- Greece: 66
- Belgium: 65
- UK: 54
- France: 42
- Romania: 38
- Germany: 33

Gender

- 64.5% Female
- 32.5% Male
- 3% Not Specified /other
2.4 Endorsed Events

In 2023, ESTRO endorsed a total of 44 conferences, congresses, and courses, which are detailed in the Annex on page 68.
3. ESTRO Workshops

3.1 2023 Physics Workshop: Science in development
13-14 October 2023 | Turin, Italy

The physics workshops, organised by the ESTRO Physics Committee, are designed to create forums for discussion of topics of interest, the sharing of ideas, the development of joint projects and interaction with industrial partners.

These workshops aim to foster communication, awareness and appreciation between the disciplines in the light of the greatest current (and old) challenges and the latest advances in methodologies and experimental approaches.

Five tracks ran in parallel:
- Temporal optimization and personalization of the radiation treatment course
- AI for the fully automated radiotherapy treatment chain
- Towards a consensus on pre-treatment verification in particle therapy
- Quality assurance for online adaptive radiotherapy
- Methods to combine and sum external beam and brachytherapy dose distributions.
3.2 Climate Change Webinars

_In collaboration with the Physics Workshop 2023_

27 June & 3 October 2023 | Online

In collaboration with the Physics Workshop 2023, ESTRO organised a series of two online webinars addressing the pressing issue of Climate Change.

The purpose of these sessions was not only to generate awareness about the climate crisis but also to explore its relationship with healthcare, specifically in the radiation oncology area.

The themes of the webinars were as follows:

- Webinar 1: Radiotherapy and oncology, the climate crisis
- Webinar 2: Carbon footprint of international radiotherapy centres

Beyond disseminating information, the aim of these Climate Change Webinars was to cultivate a network of like-minded colleagues dedicated to fostering sustainability in the field of radiation oncology. This initiative reflects ESTRO’s ongoing commitment to staying informed, responsible, and actively engaged in addressing critical global challenges.

---

492 Participants

Top 5 countries (Participants)

<table>
<thead>
<tr>
<th>Country</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>UK</td>
<td>130</td>
</tr>
<tr>
<td>Greece</td>
<td>46</td>
</tr>
<tr>
<td>India</td>
<td>34</td>
</tr>
<tr>
<td>India</td>
<td>34</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>16</td>
</tr>
<tr>
<td>Italy</td>
<td>14</td>
</tr>
</tbody>
</table>

---
3.3 2023 GEC-ESTRO Workshop - Brachytherapy: Making the difference
16-17 November 2023 | Prague, Czech Republic

The GEC*-ESTRO annual workshop is now a hallmark platform, fostering invaluable networking opportunities with the eight GEC-ESTRO working groups: Gastrointestinal, Brachy-HERO, BRAPHYS, Breast, Gynae, Head and Neck, Skin, UroGEC.

The 2023 edition showcased various facets of brachytherapy, delving into new advancements, with each working group presenting and analysing site-specific aspects of modern image-guided brachytherapy. The focus was on developments and outcomes that distinctly favour brachytherapy, including modern imaging perspectives, re-irradiation techniques, results from phase 2 and phase 3 trials, analyses demonstrating brachytherapy's potential for organ and function preservation, and insights into education initiatives in brachytherapy across Europe.

Beyond the scientific programme, attendees also enjoyed networking sessions, including engagement opportunities with industry professionals.

*GEC : The Groupe Européen de Curiethérapie

229 Delegates

217 Participants
12 Company Delegates

Top 5 disciplines

- 43% Radiation Oncologists
- 20% Medical Physicists
- 9% Industry
- 8% Clinical Oncologists
- 8% RTTs (Radiation Therapists), RT nurses
- 12% Other

Top 5 countries (Participants)

- The Netherlands: 21%
- UK: 20%
- Germany: 16%
- Poland: 10%
- Spain: 9%

The GEC* : The Groupe Européen de Curiethérapie
PUBLICATIONS

1. The Green Journal

Editor-in-chief: Michael Baumann (Heidelberg, Germany)

Radiotherapy & Oncology, known as the Green Journal, is the flagship publication in ESTRO's family of journals. It covers all aspects of radiation oncology, publishing themed issues, editorials and correspondence, as well as original research and review articles.

Article transfer service to CtRO, PhiRO and TipsRO

For manuscripts not selected for publication in Radiotherapy & Oncology, authors have the opportunity to choose to have their manuscript transferred to an ESTRO open access publication.

Submitted papers

Evolution of the number of articles submitted

Submitted articles per continent

1,986 submitted manuscripts
- 414 Accepted
- 1,497 Rejected
- 43 Withdrawn or removed

78% REJECTION RATE

247 (16%) of the rejected articles were offered to their authors for transfer to ctRO, phiRO or tipsRO

77 (31%) of these articles were accepted for publication in the open access journals.

55% Asia
28% Europe
13% North and Central America
2% Oceania
1% Africa
1% South America
ACCEPTED PAPERS

Top 5 countries of accepted papers

- China: 65
- USA: 55
- The Netherlands: 53
- Germany: 31
- UK: 23

The region and country are derived by affiliation of the corresponding author

IMPACT FACTOR

Evolution impact factor

- 2012: 4,520
- 2013: 4,857
- 2014: 4,363
- 2015: 4,817
- 2016: 4,328
- 2017: 4,942
- 2018: 5,252
- 2019: 4,956
- 2020: 6,280
- 2021: 6,901
- 2022: 5,700

2023 impact factor not yet known.
MOST CITED ARTICLES IN 2023
Published between 2021 and 2022

69 citations in 2023
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients
On behalf of the MACH-NC Collaborative Group
Published in 2021

45 citations in 2023
A deep learning-based auto-segmentation system for organs-at-risk on whole-body computed tomography images for radiation therapy
Xuming Chen, Shalin Sun, Narisu Bai, Kun Han, Qianqian Liu, Shengyu Yao, Hao Tang, Chupeng Zhang, Zhipeng Lu, Qian Huang, Guoji Zhao, Yi Xu, Tingfeng Chen, Xiaohui Xie, Yong Liu
Published in 2021

40 citations in 2022
Metrics to evaluate the performance of auto-segmentation for radiation treatment planning: A critical review
Michael V. Sherer, Diana Lin, Sharif Elguindi, Simon Duke, Li-Tee Tan, Jon Cacicedo, Max Dahele, Erin F. Gillespie
Published in 2021

These papers contribute to the 2023 Impact Factor.

MOST DOWNLOADED ARTICLES IN 2023
Regardless of publication date

26,417 downloads in 2023
ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma
Published in 2021

19,308 downloads in 2023
Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines
Published in 2014

15,804 downloads in 2023
The tubarial salivary glands: A potential new organ at risk for radiotherapy
Published in 2021

TOP ARTICLES BY SOCIAL MEDIA ATTENTION *
Regardless of publication date

250,104 social media attention in 2023
MITK Phenotyping: An open-source toolchain for image-based personalized medicine with radiomics
Michael Götz, Marco Nolden, Klaus Maier-Hein
Published in 2018

221,935 downloads in 2023
The tubarial salivary glands: A potential new organ at risk for radiotherapy
Published in 2021

186,031 downloads in 2023
Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014
Published in 2018

*Social Media Attention is captured as a lifetime metric showing cumulative views, shares, likes comments etc. from publication up to YTD, regardless of publication date.
2. Open access journals

ESTRO and Elsevier offer three open access journals that foster the dissemination of research in areas of importance to the Society’s membership.

All members of ESTRO are eligible for a discounted fee to publish a paper in any of the three open access journals.

Authors of manuscripts submitted to *Radiotherapy & Oncology* that were not withheld for publication may be offered the opportunity to have their manuscript transferred to *ctRO*, *phiRO* or *tipsRO*. The decision on whether or not to go ahead with this transfer rests with the author of the article.
2.1 Clinical & Translational Radiation Oncology (ctRO)

Co-editors-in-Chief: Pierre Blanchard (Villejuif, France) and Daniel Zips (Berlin, Germany)

Clinical & Translational Radiation Oncology features research on all aspects of clinical and translational radiation oncology, particularly new developments in experimental radiobiology, clinical interventions and treatments. This includes imaging and biomarker studies with a clinical endpoint, as well as research results from data sciences, epidemiology and oncopolicy.

2022 Impact Factor: 3.1

2023 impact factor not known yet.
### MOST CITED ARTICLES IN 2023

Published between 2021 and 2022

<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Year</th>
<th>2023 Citations</th>
</tr>
</thead>
<tbody>
<tr>
<td>The technical design and concept of a PET/CT linac for biology-guided radiotherapy</td>
<td>Oluwaseyi M. Oderinde, Shervin M. Shirvani, Peter D. Olcott, Gopinath Kuduvalli, Samuel Mazin, David Larkin</td>
<td>2021</td>
<td>23</td>
</tr>
<tr>
<td>Evaluation of deep learning-based multiparametric MRI oropharyngeal primary tumor auto-segmentation and investigation of input channel effects: Results from a prospective imaging registry</td>
<td>Kareem A. Wahid, Sara Ahmed, Renjie He, Lisaanne V. van Dijk, Jonas Teuwen, Bridg A. McDonald, Vivian Salama, Abdallah S.R. Mohamed, Travis Salzillo, Cem Dede, Nicolette Taku, Stephen Y. Lai, Clifton D. Fuller, Mohamad A. Nasir</td>
<td>2021</td>
<td>18</td>
</tr>
<tr>
<td>Whole Brain Irradiation or Stereotactic RadioSurgery for five or more brain metastases (WHOBIS-STER): A prospective comparative study of neurocognitive outcomes, level of autonomy in daily activities and quality of life</td>
<td>Gianluca Ferrini, Anna Viola, Vito Valenti, Antonella Tripoli, Laura Molino, Valentina Anna Marchese, Salvatore Ivan Illari, Giuseppina Rita Borzì, Angela Prestifilippo, Giuseppe Emmanuele Umana, Emanuele Mortarana, Gianluca Mortellaro, Giuseppe Ferrera, Alberto Cacciola, Sara Lillo, Antonio Pontoriero, Stefano Pergolizzi, Silvana Parisi</td>
<td>2021</td>
<td>16</td>
</tr>
</tbody>
</table>

These papers contribute to the 2023 Impact Factor.

### MOST DOWNLOADED ARTICLES IN 2023

Regardless of publication date

<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Year</th>
<th>2023 Downloads</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESTRO-ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer</td>
<td>Dal Pra, A.; Dirix, P.; Khoo, V.; Carre, C.; Cozzarini, C.; Fonteyne, V.; Ghadjar, P.; Gomez-Ilturriaga, A.; Panebianco, V.; Zapatero, A.; Bossi, A.; Wiegel, T.</td>
<td>2023</td>
<td>4,587</td>
</tr>
</tbody>
</table>

### TOP ARTICLES BY SOCIAL MEDIA ATTENTION *

Regardless of publication date

<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Year</th>
<th>Social Media Attention</th>
</tr>
</thead>
</table>

*Social Media Attention is captured as a lifetime metric showing cumulative views, shares, likes comments etc. from publication up to YTD, regardless of publication date.
Physics & Imaging in Radiation Oncology (phiRO)

Co-editors-in-Chief: Ludvig Muren (Aarhus, Denmark) and Daniela Thorwarth (Tübingen, Germany)

Physics & Imaging in Radiation Oncology focuses on medical physics and imaging in radiation oncology. The journal publishes original research articles, reviews, technical notes, short communications and correspondence.

In June 2023, phiRO has achieved its first Impact Factor: 3.7. This recognition reinforces phiRO as an impactful journal highlighting the high quality and relevance of the published papers.

Submitted papers

Evolution of the number of articles submitted

<table>
<thead>
<tr>
<th>Year</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>78</td>
<td>62</td>
<td>133</td>
<td>153</td>
<td>120</td>
<td>233</td>
</tr>
</tbody>
</table>

Accepted papers

Top 5 countries of accepted papers

- The Netherlands: 24
- USA: 17
- Germany: 11
- UK: 8
- Switzerland: 8

Submitted articles by region

- 53% Europe
- 25% Asia
- 18% North and Central America
- 3% Oceania
- 0.5% Africa
- 0.5% South America

40% Rejection Rate
MOST CITED ARTICLES IN 2023
Published between 2021 and 2022

22 citations in 2023
A systematic review and quality of reporting checklist for repeatability and reproducibility of radiomic features
- 2021

15 citations in 2023
Development and evaluation of radiotherapy deep learning dose prediction models for breast cancer
Nienke Bakx, Hanneke Bluemink, Els Hagelaar, Maurice van der Sangen, Jacqueline Theuws, Coen Hurkmans
- 2021

15 citations in 2023
Oropharyngeal primary tumor segmentation for radiotherapy planning on magnetic resonance imaging using deep learning
Roque Rodríguez Outeiral, Paula Bos, Abrahim Al-Mamgani, Bas Jasperse, Rita Simões, Uulke A. van der Heide
- 2021

These papers contribute to the 2023 Impact Factor.

MOST DOWNLOADED ARTICLES IN 2023
Regardless of publication date

2,970 downloads in 2023
Machine learning applications in radiation oncology
Field, M.; Hardcastle, N.; Jameson, M.; Aherne, N.; Holloway, L.
- 2021

2,729 downloads in 2023
Relationship between dosimetric leaf gap and dose calculation errors for high definition multi-leaf collimators in radiotherapy
Kim, J.; Han, J.; Hsia, A.; Li, S.; Xu, Z.; Ryu, S.
- 2018

2,322 downloads in 2023
In vivo dosimetry in external beam photon radiotherapy: Requirements and future directions for research, development, and clinical practice
Olaciregui-Ruiz, I.; Beddar, S.; Greer, P.; Jornet, N.; McCurdy, B.; Palva-Fonseca, G.; Mijnheer, B.; Verhaegen, F.
- 2020

TOP ARTICLES BY SOCIAL MEDIA ATTENTION *
Regardless of publication date

186,116 social media attention in 2023
Characterisation of a synthetic diamond detector for end-to-end dosimetry in stereotactic body radiotherapy and radiosurgery
Maddison Shaw, Jessica Lye, Andrew Alves, Stephanie Keehan, Joerg Lehmann, Maximilian Hanlon, John Kenny, John Baines, Claudiu Porumb, Moshi Geso, Rhonda Brown
- 2021

185,949 social media attention in 2023
Dose to medium in head and neck radiotherapy: Clinical implications for target volume metrics
Nicholas Hardcastle, Atousa Montaseri, Jenny Lydon, Tomas Kron, Glen Osbourne, Georgina Casswell, David Taylor, Lisa Hall, Lachlan McDowell
- 2019

185,924 social media attention in 2023
A single neural network for cone-beam computed tomography-based radiotherapy of head-and-neck, lung and breast cancer
- 2020

*Social Media Attention is captured as a lifetime metric showing cumulative views, shares, likes comments etc. from publication up to YTD, regardless of publication date.
2.3 Technical Innovations & Patient Support in Radiation Oncology (tipsRO)

Editor-in-Chief: Michelle Leech (Dublin, Ireland)

Technical Innovations & Patient Support in Radiation Oncology offers radiation therapists, nurses and allied health professionals a forum for the publication of original research, case reports, practice development and health evaluation articles, reviews, short communications, technical notes and correspondence on topics including treatment planning and workflows, treatment delivery and verification, supportive care, psycho-oncology, education and training.

**SUBMITTED PAPERS**

Evolution of the number of articles submitted

<table>
<thead>
<tr>
<th>Year</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>19</td>
<td>34</td>
<td>51</td>
<td>65</td>
<td>67</td>
<td>71</td>
</tr>
</tbody>
</table>

**ACCEPTED PAPERS**

Top 6 countries of accepted papers

- The Netherlands: 5
- Canada: 3
- UK: 3
- USA: 3
- Ireland: 2
- Australia: 2

47% REJECTION RATE
MOST CITED ARTICLES IN 2023
Published between 2020 and 2021

14 citations in 2023
Dosimetric analysis of Deep Inspiratory Breath-hold technique (DIBH) in left-sided breast cancer radiotherapy and evaluation of pre-treatment predictors of cardiac doses for guiding patient selection for DIBH
Soujanya Ferdinand, Monidipa Mondal, Suman Mallik, Jyotirup Goswami, Sayan Das, Kazi S. Manir, Arijit Sen, Soura Palit, Papai Sarkar, Subhayani Mondal, Suresh Das, Bipasha Pal
2021

13 citations in 2023
Effects of immersive virtual reality exposure in preparing pediatric oncology patients for radiation therapy
Michelle Tennant, Nigel Anderson, George J. Youssef, Laura McMillan, Renae Thorson, Greg Wheeler, Maria C. McCarthy
2021

10 citations in 2023
Feasibility of surface guided radiotherapy for patient positioning in breast radiotherapy versus conventional tattoo-based setups- a systematic review
Wesley Naidoo, Michelle Leech
2022

Most downloaded articles in 2023
Regardless of publication date

3,196 downloads in 2023
ESTRO-ACROP guideline for positioning, immobilisation and setup verification for local and loco-regional photon breast cancer irradiation
2023

3,049 downloads in 2023
Side effects in breast implants related to radiotherapy in breast cancer reconstructive surgery
Winkel de Faria Castro Fleury, E., Jasmin Huanca Bernal, K., Lucena Miranda Madeiro, A., Luis Cervera Ocana, W., Carlos Vendramini Fleury, J., Caobianco, L.
2023

2,414 downloads in 2023
Feasibility of surface guided radiotherapy for patient positioning in breast radiotherapy versus conventional tattoo-based setups- a systematic review
Wesley Naidoo, Michelle Leech
2023

These papers contribute to the 2022 Impact Factor.

TOP ARTICLES BY SOCIAL MEDIA ATTENTION *
Regardless of publication date

186,006 social media attention in 2023
Practical brachytherapy solutions to an age-old quandary
N. Thiruthaneeswaran, H. Tharmalingam, P.J. Hoskin
2020

185,982 social media attention in 2023
International survey; current practice in On-line adaptive radiotherapy (ART) delivered using Magnetic Resonance Image (MRI) guidance
H.A. McNair, T Wiseman, E Joyce, B Peet, R.A. Huddart
2020

185,980 social media attention in 2023
A Prioritization Framework for the Analysis of Near Misses in Radiation Oncology
Brian Liszewski
2020

*Social Media Attention is captured as a lifetime metric showing cumulative views, shares, likes comments etc. from publication up to YTD, regardless of publication date.
The ESTRO Newsletter is published online on the ESTRO website. It provides a more informal space for the radiation oncology community to read about the latest developments in the field.

In each issue, expert editors, selected from the membership, curate contents for themed disciplinary ‘Corners’ or report on specific topics. The newsletter typically includes information on the latest advances in research and practice, interviews with key opinion leaders, conference findings, a selection of research papers and paper reviews.

Find all articles on the ESTRO Website:
www.estro.org/About/Newsroom/Newsletter

Top five most read corners in 2023
1. Read it before your patients
2. Conferences
3. RTT
4. Brachytherapy
5. Young ESTRO

Top 5 most read articles in 2023

1. CONFERENCES CORNER
Second Middle East Radiation Oncology Society (MESTRO) Conference 2023
Saad Alrashidi, Saudi Arabia

2. READ IT BEFORE YOUR PATIENTS
Disease-Free Survival Of Patients With Muscle Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preserving Therapy: A Nationwide Study
Int J Radiat Oncol Biol Phys 2023

3. RTT CORNER
Value of the Use of Surface-Guided Radiation Therapy in Radiation Oncology
Melis Gençtürk

4. ROSQ CORNER
Quality Assurance And Quality Control In Radiotherapy – Basic Principles
Velimir Karadza

5. CONFERENCES CORNER
ESTRO 2023 Report - Prostate SBRT
Thomas ZILLI
RESEARCH & DISSEMINATION

ESTRO is committed to supporting research relevant to its members. The scope of ESTRO involvement will vary with the research topic, the type of research activity, and the level of support requested.

On the next pages are explanations of research activities in which ESTRO was involved in 2023.

EPTN

The European Particle Therapy Network (EPTN) is a task force of ESTRO. The task force was launched in 2017 as the number of clinical proton-therapy facilities in Europe was increasing rapidly. Most of these centres are hospital-based, and many are academic.

On the 26 and 27 October 2023, the EPTN held its ninth Annual Meeting and workshops for a two-day event in Manchester, UK. The Annual Meeting was held in the Christie Centre in Manchester and attracted 70 participants from 15 different European countries.

Three workshops were also organised the day prior to the Annual Meeting in Manchester, dedicated to Adaptive Proton Therapy, Evidence-based Proton Therapy, and Beyond Physical Dose.

You can read about progress across the WPs, updates from European Union (EU) projects and other initiatives of interest to the network at this link: www.estro.org/Science/Activities/EPTN
ReCare (EORTC 2011-RP) is a cohort of the E²-RADIatE platform that focuses on cancer patients who are treated with high-dose re-irradiation.

ReCare's primary objective is to evaluate re-irradiated tumour control as well as safety of re-irradiation with regards to early and late toxicity for the different anatomic groups.

2023 marked the activation of the first site for ReCare.

OligoCare (EORTC 1822-RP) is a pragmatic observational cohort study to evaluate radical radiotherapy for patients with oligometastatic disease.

The main objective is to identify patient, tumour, diagnostic and treatment characteristics impacting overall survival, when all cancer sites are treated with definitive local therapy.

On 11 April 2023, the RP-1822 OligoCare cohort successfully enrolled its 2000th patient, marking a significant milestone for the cohort initiated in 2019.

The OligoCare cohort enrolled 701 patients in 2022 alone. The average accrual rate of patients has been an impressive 58 per month.

OligoCare (EORTC 1822-RP)

E²-RADIatE comprises two innovative cohorts:
- OligoCare (EORTC 1822-RP)
- ReCare (EORTC 2011-RP).

OligoCare is a pragmatic observational cohort study to evaluate radical radiotherapy for patients with oligometastatic disease.

E²-RADIatE (EORTC 1811 study) is a platform that collects real-world data through prospective data registries in radiotherapy. A collaboration between the European Organisation for Research and Treatment of Cancer (EORTC) and ESTRO, it aims to be a pan-European infrastructure and a more efficient framework across the field of radiation oncology to generate robust data in cancer treatment and to further develop and integrate the discipline into therapeutic strategies.

E²-RADIatE comprises two innovative cohorts:
- OligoCare (EORTC 1822-RP)
- ReCare (EORTC 2011-RP).
EU-REST

The EU-REST project (European Union Radiation, Education, Staffing & Training) started on 1 September 2022 and will last until 31 August 2024.

The project aims to provide an analysis of workforce availability, education, and training needs to ensure quality and safety aspects of medical applications involving ionising radiation in the EU, and foresees the development of staffing and education / training guidelines for key professional groups involved in ensuring radiation safety and quality of medical radiation applications in the EU member states.

MARLIN

The 24-month MARLIN project (Medical Applications of Radiation – Learning from Incidents and Near Misses), started 1 January 2023, will support the implementation of Council Directive 2013/59/Euratom and provide a comprehensive description of the current status of incident reporting.

It is important that the use of ionising radiation in the diagnosis and treatment of diseases is carefully monitored and measures are taken to minimise both the frequency and harm caused by accidental or unintended exposures to patients, according to the relevant articles of the Basic Safety Standards Directive (BSSD). The use of incident learning systems (ILSs), anonymous notification systems where incidents and near misses can be investigated and possible flaws in a process can be identified and rectified, will be studied with regard to their compliance with the BSSD and other regulatory requirements and their role in improving patient safety.
GUIDELINES

The following guidelines were developed under the auspices of the Guidelines Committee in 2023

- An ESTRO-ACROP guideline on quality assurance and medical physics commissioning of online MRI guided radiotherapy systems based on a consensus expert opinion
- ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer
- ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma
- GEC-ESTRO (ACROP) – ABS - CBG consensus brachytherapy target definition guidelines for recurrent endometrial and cervical tumors in the vagina
- Treatment of oligometastatic non-small cell lung cancer: An ASTRO/ESTRO clinical practice guideline

ESGO/ESTRO/ESP guidelines for the management of patients with cervical cancer – Update 2023
- ESTRO-ACROP guideline on Prostate Bed Delineation for Postoperative Radiotherapy in Prostate Cancer
- ESTRO-ACROP guideline: recommendations on implementation of breath-hold techniques in radiotherapy
- ESTRO/ESGO/SIOPe guidelines for the management of patients with vaginal cancer
- ESTRO-ACROP guideline for positioning, immobilisation and setup verification for local and loco-regional photon breast cancer irradiation
- ESTRO-ACROP consensus recommendation on the target volume definition for radiation therapy of macroscopic prostate cancer recurrences after radical prostatectomy
- ESTRO clinical practice guideline: Stereotactic body radiotherapy for spine metastases

The following guidelines were endorsed by the Guidelines Committee in 2023

- Definition and diagnosis of oligometastatic bladder cancer: A Delphi consensus study endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty
- Partial breast irradiation for patients with early-stage invasive breast cancer or ductal carcinoma in situ: An ASTRO clinical practice guideline
- ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer
- European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. treatment–update 2023 - Authors on behalf of EADO, EDF, ESTRO, UEMS, EADV and EORTC
- European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma: update 2023 - Authors on behalf of EADO, EDF, ESTRO, UEMS and EADV
The ESTRO School’s mission is to:
- improve, professionalise and harmonise knowledge and practice in radiation oncology and associated professions in Europe and beyond.

To this end, the School:
- offers a wide range of live educational activities and online educational resources that enable professionals worldwide to acquire the most recent knowledge, skills and competencies in their daily practice.
- supports the implementation of the European Core Curricula with education and training programmes that target both young and senior radiation oncology professionals to deliver high-quality treatment and care to cancer patients.

Several new formats have been developed to enrich the educational programme and make it accessible to everyone:

- Pre-recorded lectures
- Modules spreading the programme over several weeks, or condensed in a few days
- Live online lectures
- Live broadcasting of some courses with the faculty members teaching live at the ESTRO office (using the ONLINE PLUS format)
1. 2023 ESTRO SCHOOL ACTIVITIES AT A GLANCE

ESTRO School 2023 in figures

- 3,993 Participants
- 2,503 at live and online courses
- 509 at FALCON Workshops
- 102 at On demand courses
- 604 at Pre-meeting courses at ESTRO 2023
- 275 at Contouring workshops at ESTRO 2023

School activities

- 35 teaching courses (live and online)
- 12 FALCON contouring workshops
- 6 Pre-meeting courses at ESTRO 2023
- 5 Contouring workshops at ESTRO 2023
- 3 On demand courses

New developments in 2023

1/ Introducing On-Demand Courses
This new format provided online access to all course materials from three past teaching courses: Target Volume Determination – from Imaging to Margins, Haematological Malignancies, and Evidence-Based Radiation Oncology.

2/ A new course
Introducing the Dosimetry Audit Course, launched in April 2023.

3/ Leadership Transition: Luca Boldrini Appointed New Chair of Education Council
In the autumn, Luca Boldrini was appointed the new Chair of the Education Council. He will officially succeed Jesper Eriksen, who finished his term, at the ESTRO 2024 annual congress, reinforcing ESTRO’s dedication to leadership transitions and continuity in educational excellence.
2. TEACHING COURSES

2.1 A Rich Palette on Offer

The portfolio of live teaching courses includes basic and more advanced courses that are targeted at the various radiation oncology professions.

The topics cover the main areas of radiation oncology and multidisciplinary cancer treatment courses on:

- Radiotherapy treatment planning and delivery: external beam and brachytherapy
- Multimodal cancer treatment, in general and also site-specific treatment
- Imaging
- Best practice
- Research
- Biological aspects of radiation oncology.
2.2 2023 Courses
Live and online

Top 5 most attended courses

- 192 participants
  Basic Clinical Radiobiology

- 169 participants
  Implementation and Practice of Image-guided Stereotactic Body Radiotherapy

- 109 participants
  Advanced Treatment Planning

- 103 participants
  Palliative Care and Radiotherapy

- 103 participants
  Image-Guided and Adaptive Radiotherapy

2,503 Participants

30 Live courses
3 Online courses
2 Hybrid courses
Number of courses and participants over the years

The graphs on this page only represent participation in **live and online courses**. They don’t include participation in other School activities such as contouring workshops, educational events at the annual congress, and on-demand courses.

### Participant Origin Distribution by Continent

- **78% Europe**
- **12% Asia**
- **6% Oceania**
- **12% Asia**
- **2% Americas**
- **2% Africa**

### Top 10 countries - Courses online and onsite

- The Netherlands: 170
- Romania: 151
- Australia: 100
- Belgium: 96
- UK: 93
- Poland: 90
- Switzerland: 83
- Sweden: 68
- Spain: 68
- Portugal: 64

The graphs on this page only represent participation in live and online courses. They don’t include participation in other School activities such as contouring workshops, educational events at the annual congress, and on-demand courses.
2.3 Pre Meeting Courses

ESTRO 2023

The first day of the annual congress is always dedicated to teaching courses. Six pre-meeting courses took place onsite in Vienna on 12 May 2023 at the occasion of ESTRO 2023.

Number of participants per pre-meeting course

<table>
<thead>
<tr>
<th>Course</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTERDISCIPLINARY - SBRT/SRS: a one-day bootcamp</td>
<td>298</td>
</tr>
<tr>
<td>PHYSICS - Practical implementation of complex systems and processes into the clinic</td>
<td>102</td>
</tr>
<tr>
<td>RTT &amp; YOUNG - Creating a thriving interdisciplinary team in radiation oncology, ready for the future</td>
<td>65</td>
</tr>
<tr>
<td>RADIOBIOLOGY - Making the most of radiation therapy combination strategies</td>
<td>54</td>
</tr>
<tr>
<td>CLINICAL - Palliative care: Patient’s and physician’s journey in the era of new treatments and radiation techniques</td>
<td>49</td>
</tr>
<tr>
<td>BRACHYTHERAPY - The evolving role of brachytherapy for cancers of the GI tract</td>
<td>36</td>
</tr>
</tbody>
</table>

Grand Total: 604
3. E-LEARNING

3.1 Training in delineation

An accurate and precise anatomical contouring of target volume and OaRs* is of utmost importance in radiotherapy. FALCON**, ESTRO’s contouring programme, allows radiation oncology professionals to improve their contouring skills.

In using the FALCON EduCase software, trainees can compare their individual contours with those made by delineation experts and visualise the ESTRO international guidelines.

FALCON is integrated into the whole portfolio of the educational ESTRO activities:

- **Live courses**
- **Workshops at ESTRO meetings**
- **Online virtual workshops**
- **Support services** for clinical trials and development of guidelines
- **Delineation workshops for other societies** (IAEA, national societies or other societies active in the field of oncology)

* Organs at Risk
**Fellowship in Anatomic deLineation and CONtourings
3.2 Online delineation workshops

Top 5 countries

- UK: 75
- Australia: 49
- Germany: 40
- Ukraine: 39
- Romania: 19

Geographic distribution of participants at online blended FALCON workshops

- 65% Europe
- 14% Asia
- 13% Oceania
- 4.5% Americas
- 3.5% Africa

Evolution of number of participants at online delineation workshops

- 2015: 106
- 2016: 70
- 2017: 288
- 2018: 274
- 2019: 285
- 2020: 396
- 2021: 418
- 2022: 471
- 2023: 509

Participants: 509 members
- 390 members
- 121 non-members

Online delineation workshops:
- 2015: 7
- 2016: 8
- 2017: 11
- 2018: 13
- 2019: 13
- 2020: 11
- 2021: 14
- 2022: 13
- 2023: 12

Workshops
- 2023: 12

Participants
- 2023: 509
3.3 Delineation workshops at the ESTRO annual congress

ESTRO 2023

In addition to the pre-meeting courses, ESTRO offers hands-on delineation workshops in the framework of the annual congress.

275 Participants

5 Contouring workshops held onsite at ESTRO 2023

Number of participants per contouring workshop:

<table>
<thead>
<tr>
<th>Workshops</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spinal tumours SBRT</td>
<td>82</td>
</tr>
<tr>
<td>Pancreatic cancer SBRT</td>
<td>68</td>
</tr>
<tr>
<td>Primary vaginal cancer</td>
<td>46</td>
</tr>
<tr>
<td>Sarcoma</td>
<td>43</td>
</tr>
<tr>
<td>Special RTT Workshop</td>
<td>35</td>
</tr>
</tbody>
</table>

Top 5 countries

- Romania: 26
- Germany: 24
- UK: 21
- Australia: 18
- Switzerland: 17

246 members
29 non-members
With more than 9,000 radiation oncology professionals from across the world, the ESTRO membership is the heart of our Society.

ESTRO contributes to the day-to-day practice and career advancement of oncology professionals through the dissemination of the latest trends in practice, research findings and knowledge.
ESTRO offers several levels of membership, with benefits tailored to the needs of each member and their degree of involvement within the Society.

The full range of ESTRO membership benefits includes:

- Belonging to a community of more than 9,000 radiation oncology professionals
- Networking opportunities
- Subscription to *Radiotherapy and Oncology*, the Society’s journal, and reduced members’ fees for publishing in the ESTRO open access journals
- Reduced fees for attending ESTRO congresses, workshops and courses
- Online access to scientific material, including event webcasts and delineation cases
- Eligibility for mentorship programme, grants, awards, ESTRO faculties and governance positions
- Voting rights at the Society’s elections and the ESTRO General Assembly
1. Profile of ESTRO Members

Breakdown of ESTRO members by speciality

- 43.4% Radiation oncologists
- 21.1% Medical physicists
- 13.3% RTTs - nurses - dosimetrists
- 7.6% Clinical oncologists
- 1.0% Biologists
- 13.6% Other medical and non-medical specialities

The ESTRO community extends far beyond these professional radiation oncology disciplines, taking in a wide range of other professions.

This includes professionals from:
- other medical fields, such as surgeons, radiologists, medical oncologists, gynaecologists and urologists
- and non-medical fields, such as public affairs specialists.

Top 10 countries

- The Netherlands: 9.9%
- UK: 7.4%
- Switzerland: 7.0%
- Australia: 6.7%
- Germany: 6.4%
- Italy: 6.2%
- Belgium: 5.2%
- Spain: 3.9%
- USA: 3.5%
- Denmark: 3.2%
- France: 3.2%

Geographical distribution

- 71.7% Europe
- 8.9% Asia
- 7.9% Oceania
- 7.5% Americas
- 2.0% Africa
- 2.0% Unknown
In 2023, ESTRO achieved a new milestone unprecedented in its history, boasting a record membership of over 9,000 individuals.
2. A wide range of membership categories

- **54.45%**
  **INDIVIDUAL MEMBERS**
  (5,140)
  - 29.80% FULL (2,813)
    - 28.76% Active (2,715)
    - 0.9% Supporting Ambassador (85)
    - 0.14% Emeritus (13)
  - 24.65% ASSOCIATE (2,327)
    - 17.59% Affiliate (1,660)
    - 6.98% In-Training (659)
    - 0.08% Honorary (8)

- **21.83%**
  **INSTITUTIONAL MEMBERS**
  (2,061)
  77 Institutes

- **14.65%**
  **JOINT MEMBERS**
  (1,383)
  - 8.93% Joint (843)
  - 5.72% Joint In-Training (540)

- **6.44%**
  **RTT ALLIANCE MEMBERS**
  (608)
  26 National societies

- **2.62%**
  **CORPORATE MEMBERS**
  (247)
  38 Companies
3. Membership categories under the spotlight

1. Institutional membership

The institutional membership is designed for centres aiming to support their oncology teams in their professional development. It also fosters interdisciplinarity and multidisciplinarity within the departments.

With this category, centres can purchase upgraded membership packages on behalf of their employees, with very attractive conditions.

Centres also benefit from an increased visibility with:
- A dedicated institutional webpage on the ESTRO website
- A complimentary networking space in the Communities Pavilion during the annual congress
- Free online job postings
- An “ESTRO institutional member” logo.

2. Supporting ambassador membership

New institutional members in 2023:
- Belgium: university Hospital Ghent
- France: Institut de cancerologie Gustave Roussy-InsermU1030
- Germany: BAG Strahlentherapie Aschaffenburg
- Italy: Radiation Oncology unit Fatebenefratelli Isola Tiberina - Gemelli Isola ART
- Romania: Institute of Oncology Prof. Dr. I Chiricuta
- Sweden: Region Västmanland
- Sweden: Sahlgrenska university Hospital - Jubileumskliniken
- Switzerland: La Tour Medical Group, Meyrin
- Turkey: Marmara University Hospital
- UK: Guy’s and St Thomas’ NHS Foundation Trust
- UK: North West Cancer Centre - Altnagelvin Area Hospital

This membership category is reserved for professionals in the field of radiation oncology who are strongly committed to supporting the ESTRO activities in the enhancement of the radiotherapy community.

161 Individuals signed up as supporting ambassadors.
3. In-Training members and members up to 40 years old

It is essential for ESTRO to invest and connect with the next generation of healthcare professionals and decision-makers.

To this end, ESTRO consolidates its collaboration with European societies representing the new generation of radiation oncology professionals and encourages them to join the society.

ESTRO In-Training members are professionals in the field of radiation oncology who are in training or full time PhD and have obtained their diploma within the last 10 years.

In 2023, 46% of ESTRO’s membership comprises professionals under the age of 41.

Illustrations of the involvement of the new generation of professionals in the ESTRO community

- **The Young Corner**
  Dedicated section in the ESTRO newsletter with news from young national societies and young members sharing their experience through meetings, travel grant reports, etc.

- **The Young Track**
  Full-day programme held during ESTRO’s annual congress, which focuses specifically on topics of interest to young professionals.

- **Opinion Panel**
  Online, bi-monthly questionnaire where panelists share their opinion on the yESTRO Committee activities and take their first step within the ESTRO community.

- **Mentoring Programme**
  Annual programme matching young, active professionals with experienced mentors, with the aim of advancing their personal and professional goals.

Breakdown of In-Training members

- **1,550 In-Training members**:
  - 659 individual In-Training
  - 351 institutional In-Training
  - 540 Joint In-Training

Evolution of In-Training members

<table>
<thead>
<tr>
<th>Year</th>
<th>Individual</th>
<th>Joint</th>
<th>Institutional</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>877</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>862</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td>1,012</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td>1,208</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2021</td>
<td>1,194</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2022</td>
<td>1,358</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2023</td>
<td>1,550</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
4. Joint membership

This category can be granted to individual members who benefit from a joint membership agreement, signed on a case-by-case basis between ESTRO and a non-European society or a young national society active in the field of radiation oncology. In 2023, ESTRO counted 1,383 joint members.

5. Corporate members

With the ESTRO Corporate membership, the industry has privileged access to the global radiotherapy and oncology community. Gold Corporate members are invited to engage with ESTRO and its community via the ESTRO Advisory Corporate Council. As council members, they have the opportunity to give their views on the clinical practice in radiation oncology and support the long-term objectives of the society.

Corporate members in 2023

- 14 gold members
- 24 regular members
Memoranda of understanding (MoUs) on science, education and membership are key agreements that enable ESTRO to establish new collaborations and nurture existing ones with other society in the field of oncology.

In 2023, ESTRO signed membership MoUs with the following national and international societies:

- Iran - ISCO, Iranian Society of Clinical Oncology
- Belgium - BeSTRO, Belgian Society for Radiotherapy & Oncology
- Chile - SOCHIRA, Sociedad Chilena de Radioterapia Oncológica
- Romania - YRROG, Young Romanian Radiation Oncology Group (RO)
- Spain - SEOR, Sociedad Española de Oncología Radioterápica
- Tunisia - STOR, Tunisian Society of Radiation Oncology

Full RTT Alliance list is available in the Annex.

In 2023, three additional national societies joined the RTT Alliance:

- Australian Society of Medical Imaging and Radiation Therapy (ASMIRT)
- Swedish Cancer Nursing Society (SiC)
- Nederlandse Verening Medische Beelvvorming en Radiotherapie (NVMBR)

Additional MoUs are being drafted and renewed in 2024.
The ESTRO Cancer Foundation (ECF) continues its efforts to foster the outreach of radiotherapy at the European level, especially by implementing the Value Based HealthCare (VBHC) project and UpLung, a project initiated in 2020. Both initiatives aim to improve the access of patients to high-quality radiotherapy treatment.
Value-Based HealthCare (VBHC) is an ESTRO/ECF – HERO project aiming at developing a framework for defining the value of radiation oncology to reflect the specificities of treatment, allowing for the optimisation of patient access to high-value developments in radiation therapy. The project commenced in 2021 and is supported by a grant from ELEKTA and VARIAN.

Innovative interventions in radiation oncology are diverse and complex in technologies, techniques, and treatment schemes. This project aims to provide a framework for defining the value in radiation oncology through defining and categorising innovations. In doing so, the project links endpoints and interventions with necessary evidence, to consequently help support policy making and reimbursement schemes, and allow for optimised patient access to radiotherapy.

Links to publications related to the project:
- Value-based radiotherapy: A new chapter of the ESTRO-HERO project
- Innovation, value and reimbursement in radiation and complex surgical oncology: Time to rethink

Utilisation of radiotherapy for Lung cancer in Europe is an ESTRO/ECF – HERO project, investigating the causes and barriers to the uptake of radiotherapy for lung cancer in Europe, with radiotherapy being recommended for more than 50% of cancer patients. The project was launched in November 2020, and is supported by a grant from AstraZeneca.

Through using quantitative and qualitative research, the UpLung project has initiated to estimate the gap in access to radiotherapy for lung cancer and analyse the structural and organisational aspects that influence the uptake of radiotherapy in Europe in the treatment of lung cancer. Through the research on the causes and barriers to the limited access to radiotherapy, the project aims at developing policy recommendations in order to improve patient outcome and closing the access gap, with an indication for radiotherapy.

A research article was published in ctRO in December 2023:
- Utilisation of radiotherapy in lung cancer: A scoping narrative literature review with a focus on the introduction of evidence-based therapeutic approaches in Europe
5 FINANCIAL REPORT
1. Treasurer’s report for 2023

Dear Friends and Colleagues,

In early 2019, I was writing the treasurer’s report for 2018 as my six-year term as treasurer was coming to an end. From a financial point of view, ESTRO was steadily growing stronger. At the time that my term had started, back in 2013, our turnover had stood at €6.5m; six years later, we were looking forward to a €9.3m turnover for 2019. That year our Society recovered from the consolidated -€1m that we had registered in 2009 with over €2m in reserves. As you might recall, we were at the start of revising the governance structure, and at the general assembly (GA) of April 2019, I was asked to extend my term until the new structure had been adopted.

Little did we know what was about to happen. In the annus horribilis, 2020, our turnover plummeted to €4.5m and the reserves were used as collateral to safeguard our cash flow. Restructuring the Society was no longer a priority, and for the sake of continuity, it was decided that a transition of treasurer was best postponed while we weathered the storm.

Today, I can safely say that we are back on track with a turnover that matches the pre-pandemic situation, and for the first time in years, we boast a robust, positive cumulative result.

This achievement is a testament to the collective efforts of all of you, who have unwaveringly supported and believed in ESTRO. With a sound governance structure firmly in place, ESTRO is ready to invest and initiate new activities, and the time has come to hand over to our capable new treasurer.

Turning to the audited accounts of 2022, which were approved at the GA of May 2023; the auditors provided an unqualified opinion. In response to their recommendation, the portfolio was revalued (-€188,000) to reflect its year-end underperformance in 2022. With operating expenses that totalled €7.282m and revenue reaching €8.001m, the net impact of income and expenditure resulted in a holding of €468k (including financial and extraordinary results). So once again we had broken even with a modest positive buffer.

Regarding 2023, the figures have been audited at the time of writing and await final approval at the GA during our annual meeting in Glasgow in May. Revenues and expenses at the end of 2023 were €8.809m and €8.292m respectively, resulting in a total net gain (including the financial and extraordinary results) of €628k. The cumulative result surpassed €800k. The ESTRO portfolio, characterised by a defensive, socially responsible investment profile, endured the impacts of the pandemic and the conflict in Ukraine (showing signs of recovery at the onset of 2024). The total reserve stood at €2.158m at the end of March 2024, a respectable figure given the prevailing economic conditions. Nonetheless, with the portfolio exhibiting minimal growth over the past decade, a reappraisal of its management seems advisable now that our financial situation has again stabilised.

Closing this report, I extend my heartfelt gratitude to each of you for your steadfast dedication to ESTRO, and to our industry partners for their unwavering support. It has been both an honour and a privilege to have served the Society as your treasurer. ESTRO is ready for the future.

Warm regards, and as always, think pink

Dirk Verellen
ESTRO treasurer
The figures presented in this report were approved at the ESTRO general assembly on 15 May 2023.

In 2022, operating revenues rose to almost €8.001 million, led by registrations at meetings and courses and exhibition subscriptions.

The financial incomes represented an amount of €8,000 while the financial charges, including bank charges and credit card commissions, represented €71,000.

The Portfolio was revalued (−€188,000) based on the auditor’s request to reflect its value at 2022-year end. With operating expenses of €7.282 million the net impact of income and expenditure is a net result of €468,000.

**Revenue**

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount (KEUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESTRO 2022</td>
<td>4,698</td>
</tr>
<tr>
<td>ICHNO-ECHNO</td>
<td>332</td>
</tr>
<tr>
<td>ESTRO School</td>
<td>784</td>
</tr>
<tr>
<td>Workshops</td>
<td>200</td>
</tr>
<tr>
<td>Memberships</td>
<td>706</td>
</tr>
<tr>
<td>Elsevier Royalties/Comm.</td>
<td>834</td>
</tr>
<tr>
<td>Other Revenues</td>
<td>447</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>8,001</strong></td>
</tr>
</tbody>
</table>

**Expenditure**

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount (KEUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESTRO 2021</td>
<td>2,456</td>
</tr>
<tr>
<td>ICHNO-ECHNO</td>
<td>297</td>
</tr>
<tr>
<td>ESTRO School</td>
<td>635</td>
</tr>
<tr>
<td>Workshops</td>
<td>135</td>
</tr>
<tr>
<td>Memberships</td>
<td>9</td>
</tr>
<tr>
<td>Governance (Commit &amp; Council)</td>
<td>105</td>
</tr>
<tr>
<td>Other Activity Costs</td>
<td>119</td>
</tr>
<tr>
<td>Employment Costs</td>
<td>2,468</td>
</tr>
<tr>
<td>General &amp; Administration</td>
<td>466</td>
</tr>
<tr>
<td>General IT (incl. Website,...)</td>
<td>213</td>
</tr>
<tr>
<td>Communication/Marketing</td>
<td>69</td>
</tr>
<tr>
<td>Elsevier Charges</td>
<td>310</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>7,282</strong></td>
</tr>
</tbody>
</table>

**Financial result**

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount (KEUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Financial Incomes</td>
<td>8</td>
</tr>
<tr>
<td>Bank &amp; Credit card charges</td>
<td>-71</td>
</tr>
<tr>
<td>Reduct. Portfolio value</td>
<td>-188</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>-251</strong></td>
</tr>
</tbody>
</table>

Net Result (Net Profit): €468
3. Cumulated result 2008 - 2023
1. Governance & constituent bodies

Board of Directors
- Anna Kirby - London, UK
- Matthias Guckenberger - Zurich, Switzerland
- Ben Slotman - Amsterdam, The Netherlands
- Uulke van der Heide - Amsterdam, The Netherlands

Scientific Council
- Estelle Troost - Dresden, Germany
- Esther Troost - Dresden, Germany

Education Council
- Kerstin Borgmann - Hamburg, Germany
- Fiona McDonald - London, UK

Professions & Partnerships Council
- Catharine Clark - Guildford, UK
- Karin Haustermans - Leuven, Belgium

Clinical Committee
- Catharine Clark - Guildford, UK

GEC-ESTRO Committee
- Vratislav Strobl - Gliwice, Poland

Physics Committee
- Anna Kirby - London, UK

Biology Committee
- Kerstin Borgmann - Hamburg, Germany

Annex
2. Staff

CEO
Alessandro Cortese

Society affairs & executive office
Chiara Gasparotto Deputy CEO
Simone De Ioanna Society Affairs Manager
Charlene Macio Society Affairs Coordinator

Education
Laura Le Parc Senior Manager Education
Agnes Delmas Committees & Education Project Manager
Karolina Kowalska Committees & Education Project Manager
Andrea Callens Committees & Education Project Manager
Mika Paimio Senior Education Project Manager
Claire Thomas Programme Administrator

Science
Eralda Azizaj Senior Manager Science
Jessica Pledge Scientific Programme Manager
Jonas Johansen Coordinator Scientific & R&D projects
Martina Montano Scientific Programme Coordinator

Membership & partnerships
Valerie Cremades Membership & Partnerships Manager
Sigríd Jacobs-Peers Programme Supervisor

Marketing & Events
Anna Belén Amoredoe Senior Manager Marketing & Events
Agostino Barracco Events Manager
Céline Dechamps Project Manager Workshops
Dina Ardiana Events Coordinator

Corporate relationships
Hanne Van Genk Exhibition Project Manager

Registration & Administration
Charlotte Guallar ESTRO Programme Administrator

Finance
Arnaud Ponsart Senior Finance Manager
Gürkan Ulusoy Accounting Coordinator
Gloria Ndayishimiye Accounting Coordinator

Human Resources
Emilie Croops Senior HR Manager

IT
Michael Beihlend IT Development Manager
Benjamin Conroy IT Support Officer

Consultants
Melissa Aikens Education
iLab-Boundary Operational Communications
Clement/Beggards Graphic Design
Cécile Haridon-Villard Strategic Communications
Evel Sarto Scientific Programme

3. Corporate members

Gold corporate members
ACCURAY
AstraZeneca PLC
BOSTON SCIENTIFIC
COXIES RADIOTHERAPY
EUKIKA INSTRUMENT AB
IBA
MIM SOFTWARE INC
OBERT INDUSTRIES
PALETTE LIFE SCIENCES
PHILIPS
S.I.T. - SOKINDO KORT TECHNOLOGIES S.P.A
SUN NUCLEAR CORPORATION
VARIAN, A SIEMENS HEALTHCAREERS COMPANY
VIEWRAY

Corporate members
Adaptiiv Medical Technologies Inc.
ALPHAI2U MEDICAL LTD
Aquilar
BRYNLAB
C-RAY POSITIONING AB
Carl Zeiss Meditec AG
Dr. Sennewald Medizintechnik GmbH
INTRAOP
KLABITY MEDICAL & EQUIPMENT CO., Ltd
LEO CANCER CARE LTD
MACROMEDICS
MED-LOGIX SRL
MICROPOS MEDICAL
Mhirian AI Oy
NELCO LTD
PTW Freiburg
RAYSEARCH Laboratories AB (Pub)
SCANDIOS AB
STANDARD IMAGING
TEMA SINERGIA S.p.A.
THERIQ
VISION RT Ltd
XSTRAHL
4. Joint members

Joint Radiation Oncology national societies and other oncology societies
- American Association of Physics in Medicine (AAPM)
- Association of Medical Physicists of India (AMPI)
- Association of Radiation Oncologists of India (AROD)
- Canadian Association of Radiation Oncology (CARO)
- International Association for the Study of Lung Cancer (IASLC)
- Iranian Society of Clinical Oncology (ISCO)
- Japanese Society for Radiation Oncology (JASTRO)
- Sociedade Chilena de Radioterapia Oncológica (SOCHIRA)
- Sociedad Mexicana de Radioterapia (SOMERA)
- Sociedade Brasileira de Radioterapia (SIBRT)
- South East Asian Radiation Oncology Group (SEAROG)

- Associazione Italiana di Radioterapia Oncologica Giovani (Young AIRO - AIRO GIOVANI)
- Belgian Society for Radiotherapy & Oncology (BELSRO)
- Israeli Society for Clinical Oncology and Radiotherapy (ISCORT)
- Portuguese Society of Oncology (SPO)
- Royal Australian and New Zealand College of Radiologists (RANZCR)
- Spanish Society for Radiotherapy and Oncology (SEOR)
- Tunisian Society of Radiation Oncology (STOR)
- Young Romanian Radiation Oncologists Group (YRROG)

Joint in Training Radiation Oncology national societies
- Associazione Italiana di Radioterapia Oncologica Giovani (Young AIRO - AIRO GIOVANI)
- Belgian Society for Radiotherapy & Oncology (BELSRO)
- Israeli Society for Clinical Oncology and Radiotherapy (ISCORT)
- Portuguese Society of Oncology (SPO)

5. RTT Alliance

European RTT Alliance Members
- Austria: Society of Radiological Technology Austria
- Belgium: Association Francophone des Infirmiers et Technologues Exerçant en Radiothérapie
- Belgium: Vereniging Verpleegkundigen Radiotherapie en Oncologie
- Bosnia and Herzegovina: Association of Medical Radiology Engineers in the Federation of Bosnia and Herzegovina
- Croatia: Croatian Association of Radiation Technologists
- Denmark: Radiologifællet
- Estonia: Estonian Society of Radiographers
- France: French Society of Radiologic Technologists
- Georgia: Association of Georgia Radiation Treatment Therapists
- Ireland: Irish Institute of Radiography and Radiation Therapy
- Italy: Italian Association of Radiation Therapists and Medical Physics Technologists
- Macedonia: Association and Chamber of Radiological Technologists of Macedonia
- Malta: Society of Medical Radiographers
- Poland: Polish Society of Electrotherapeutistics
- Portugal: Portuguese Association of Radiation Therapists
- Serbia: Serbian Society of Radiotherapy Technicians
- Spain: Spanish Society for Radiotherapy and Oncology
- Sweden: Swedish Cancer Nursing Society
- Switzerland: Swiss Association of Radiographers
- Turkey: Society of Radiation Therapy Technologists

Global RTT Alliance Members
- Australia: Australian Society of Medical Imaging and Radiation Therapy
- Brazil: Associação de Técnicos e Tecnólogos em Radioterapia do Rio Grande do Sul
- Chile: Sociedad Chilena de Radioterapia Oncológica
- India: Association of Radiation Therapy Technologists of India
- Tanzania: Radiotherapists’ Association of Tanzania
6. Institutional members

**Belgium**
- AZ Turnhout
- OLA Liège
- GZA Ziekenhuizen, Sint-Augustinus – Ixillum Kankerpreventie Antwerpen
- Institut Jules Bordet
- University Hospital Gaetleiberg (UZ Leuven)
- University Hospital Ghent
- Universiteit Ziekenhuis Brussel

**Czech Republic**
- University Hospital Hradec Kralove

**Denmark**
- Aalborg University Hospital
- Odense University Hospital

**Estonia**
- North Estonian Regional Hospital Cancer Center

**France**
- Institut de Radioprotection et de Sécurité Nucléaire
  - Centre Oscar Lambret
  - Centre Léon Bérard
- Institut Curie
- Institut de Cancérologie Gustave-Roussy-Inserm/INSERM
- Institut Gustave Roussy

**Germany**
- BAG Strahlentherapie Aschaffenburg
- Gemeinschaftspraxis für Strahlentherapie Singen-Friedrichshafen
- Klinikum Rechts Der Isar, TU Munich
- Klinik und poliklinik für Strahlentherapie und Radioonkologie (Munich)

**Hungary**
- University of Debrecen Clinic of Oncology

**Italy**
- ASU Careggi - University of Florence
- Fondazione IRCCS Istituto Nazionale Tumori
- Gemelli ART Radiotherapy Foundation polidomico Universitario A. Gemelli
- Humanitas Cancer Center
- Fondazione CNAD
- Radiation Oncology uni Karolinska Institutet Solna Tiberina – Gemelli Isola ART
- University of Brescia – ASST speciali Civil Brescia

**The Netherlands**
- Erasmus Medical Center Rotterdam
- Leiden University Medical Center
- MAASTRO
- Netherlands Cancer Institute
- Radiobouw University Medical Center
- Radiotherapiegroep (Dubbeldam)
- UMC Utrecht
- VU University Medical Center
- Maastricht University

**Poland**
- Greater Poland Cancer Center

**Portugal**
- Instituto de Oncologia Prof. Dr. L. Chiruta
- Regional Institute of Oncology (sao)

**Romania**
- Institute of Oncology Prof. Dr. I. Chirica
- University of Brescia – ASST speciali Civil Brescia

**Russia**
- TwoSloP

**Spain**
- Atrys Oncology
- Instituto Catalán de Oncología

**Sweden**
- Karolinska University Hospital
- Sjukhuset Sollentuna AB
- Region Västernorrland Sahlgrenska University Hospital - Jubileumsklinik

**Switzerland**
- Basel, St. Claraspital
- Basel, Universitätsspital Basel (USB)
- Bellinzona, Ospedale San Giovanni (BOC)
- Bern, Inselspital (Universitäts Spital Bern)
- Chur, Kantonsspital Graubünden (KSGF)
- Fribourg, Hôpital cantonal (HFR)
- Genève, Hôpital Universitaires (HUG)
- Genolier, Clinique de Genolier
- La Chaux-de-Fonds, Rèseau hospitalier neuchâtelois (RHN)
- La Tour Medical Group, Meyrin
- Lausanne, Centre Hospitalier Universitaire Vaudois (CHUV)
- Lausanne, Clinique La Source
- Lausanne, Hirslanden Clinic de Boin-Cerf
- Lugano, Gruppo Ospedaliero Montecucco
- Luzern, Kantonsspital
- Paul Scherrer Institut (PSI)
- Radio-Onkologie-Zentrum KSA-KSB
- Sion, Hopital du Valais
- St. Gallen, Kantonsspital (KSSG)
- Winterthur, Kantonsspital Winterthur (KSW)
- Zürich, Universitätsspital Zürich (USZ)

**Turkey**
- Ege University
- Marmara university Hospital

**UK**
- Guy’s and St Thomas’ NHS Foundation Trust
- North West Cancer Centre – AsthmaKan Area Hospital
- The Institute of Cancer Research
- Velindre University NHS Trust
- Western General Hospital, Edinburgh Cancer Centre
7. Radiotherapy and Oncology and open access journals

Editors
Marianne Aznar - Manchester, UK
Rob Deutsch - Groningen, The Netherlands
Eric Deutsch - Villejuif, France
Dietmar Georg - Vienna, Austria
Karin Haustermans - Leuven, Belgium
Peter Hoskin - Northwood, UK
Albert van der Kogel - Madison, USA
Mehrdad Krause - Dresden, Germany
Eric F. Langgau - Lille, France
Anne W. M. Lee - Shenzhen, China
Steffen Löck - Dresden, Germany
Birgitte Ottesen - Aarhus, Denmark
Vincenzo Valentini - Roma, Italy
Ullke Van der Hede - Amsterdam, The Netherlands

Editorial Board
Markus Aber - Heidelberg, Germany
Anne Appelt - Leeds, UK
Pierre Blanchard - Villejuif, France
Michel Bulla - Grenoble, France
Josep M. Borras - Barcelona, Spain
Thomas Bortfeld - Boston, USA
Jean Boursin - Lausanne, Switzerland
Michael Braden - Würzburg, UK
Jan Bussink - Nijmegen, The Netherlands
Rebecca Bultot - Dresden, Germany
Federico Calvo - Madrid, Spain
Anthony Chaobrun - Glasgow, UK
Javiera M. Cepeda - Kielce, Poland
Olav Dahl - Bergen, Norway
Dirk De Bogaerts - Maastricht, The Netherlands
Ahmad Ebrahimi - Ann Arbor, USA
Sara Fattahi - Guildford, UK
Claudio Fornero - Milano, Italy
Emmanuel Fokas - Frankfurt am Main, Germany
Daniel Richard Gomez - Houston, USA
Alfonso Gomez-Iturriaga - Bilbao, Spain
Car Gryau - Aarhus, Denmark
Vincent Grégoire - Lyon, France
Anca-Ligia Grosu - Freiburg, Germany
Matthias Guckenberger - Zurich, Switzerland
Xiashan Hao - Tianjin, China
Semi Harrabi - Heidelberg, Germany
Ben Heijmen - Rotterdam, The Netherlands
Coen W. Hurkmans - Eindhoven, The Netherlands
Gert De Meerleer - Leuven, Belgium
Bernard J. Mijnheer - Amsterdam, The Netherlands
Joanna Kazmierska - Poznan, Poland
Lucyna Kępka - Warsaw, Poland
Tommy Knös - Lund, Sweden
Tommy Kron - Melbourne, Australia
Philippa Lambit - Maastricht, The Netherlands
Johannes A. Langenbjörk - Groningen, The Netherlands
Michel Lejue - Dublin, Ireland
Zhongxing Liao - Houston, USA
Yvette van der Linden – Leiden, The Netherlands
Philipp Maingon – Paris, France
Gert de Meester – Leuven, Belgium
Bernard J. Mijnheer – Amsterdam, The Netherlands
Giuseppe Minetti - Siena, Italy
Gerard C. Morton – Toronto, Ontario, Canada
Ludwig Muren – Aarhus N, Denmark
Ursula Nimetz - Freiburg, Germany
Maximilian Niyazi – Munich, Germany
Bradley R. Pieters – Amsterdam, The Netherlands
Philip Poortmans – Wilrijk-Antwerp, Belgium
Richard Poller – Vienna, Austria
Nina Sale – Barcelona, Spain
Carl Sandblom – Brussels, Belgium
Frank André Siebert – Vienna, Austria
Markus Stolk – Vienna, Austria
Kari J. Tanderup – Aarhus, Denmark
Dirk Vordermark – Halle, Germany
Conchita Vens – Amsterdam, The Netherlands
Marcel Werhaj – Eindhoven, The Netherlands
Dirk Vordermark – Halle, Germany

Past Editors
Harry Bartelink
Jens Overgaard
Emeritus Physics Editor
David I. Themes - Leeds, UK

Emeritus Editors
Harry Bartelink - Heidelberg, Germany
Jens Overgaard - Aarhus, Denmark
8. Awards

ESTRO Award Lectures
- Emmanuel Van der Schueren Award: Li Yee Tien, UK
- Jens Overgaard Legacy Award: Vincenzo Valentini, Italy
- Donald Hollywood Award: Arnaldo de Leeuw, The Netherlands
- Klaas Bruur Award: Cai Grau, Denmark
- Interdisciplinary Award: Uffe van der Weide, The Netherlands
- GEC-ESTRO Heliom 192 Award: Gyorgy Kovacs, Germany

Regaud award
Etz, Deutches, France

Award Presentations
- Lifetime Achievement Awards: José Perge Calafat, Spain; Catharina West, UK; Eduard Zubirr, Austria
- Honorary Member Awards: Sandra Cermova, USA; Boguslaw Maciejewski, Poland; Thomas Merchants, USA

Company Awards
- ESTRO Elekta Brachytherapy Award: Manus Marxand, The Netherlands
- GEC-ESTRO Best Junior Presentation - sponsored by Elekta Brachytherapy: Stefan Sibey, Austria

Young Researcher Awards
- ctRO Award - sponsored by Elsevier: Anahit Abalayan, UK
- phiRO Award - sponsored by Elsevier: Brum Cella, Belgium
- tipRO Award - sponsored by Elsevier: Rachel Brooks-Pearson, UK

9. Newsletter

Corners’ Editors
Read it Before Your Patients Corner
- Hans Kaanders
- Philippa Lamber
- Evert van Limbergine

Physics Corner
- Laura Cella
- Alan Mowilliam
- Katherine Raw-Ralesden
- Ye Zhang

Brachytherapy Corner
- Åsa Carlsson Tedgren
- Georgina Fröhlich
- Peter Hoskin
- Bradley Pieters

RTT Corner
- Sophie Boisbouvier
- Ilya Cunl
- Elizabeth Sode
- Isabel Lubato
- Ludwig Van Den Berghhe

Biology Corner
- Biology Committee

ROSQ (Radiation Oncology Safety and Quality) Corner
- Sophie Perreyk

ESTRO School Corner
- Education team
- Young ESTRO Corner: Jenny Bertholet
- Barbara Temanik
10. Endorsed events in 2023

Cervix cancer BT Teaching course  
1 Sept 2022 - 1 Jan 2023 | Online

PSI Winter School for Protons 2023  
15-20 January 2023 | Bad Zurzach, Switzerland

15th BtCC  
19-21 January 2023 | Cairo, Egypt

AI meets Head & Neck Oncology  
9-14 February 2023 | Lucasanne, Switzerland

CT Imaging workshop  
29-31 March 2023 | Maastricht, The Netherlands

Think Hadros: discovering Hadrontherapy within Multidisciplinarity  
15 February 2023 | online

Recurrence After Radical Treatment (RART) - 3rd Edition  
24-25 March 2023 | Katowice, Poland and online

SprintRAD2023, on Image synthesis for radiotherapy  
April-Sep 2023

Recurrence After Radical Treatment (RART) - 4th Edition  
12-14 April 2023 | Katowice, Poland

The 15th International Netherlands Cancer Institute Head and Neck Cancer Symposium  
20-21 April 2023 | Amsterdam, The Netherlands

Brachytherapy Treatment: Techniques: Procedures and Planning  
28-29 April 2023 | Ludhiana, India

Total Body Irradiation: from 2D to 3D and beyond  
5-6 June 2023 | Utrecht, The Netherlands

Retradation - Still navigating uncharted waters  
15 June 2023 | Zürich, Switzerland

Recommendations on integration of radiation therapy with targeted treatments for breast cancer consensus meeting  
16-17 June 2023 | Rome, Italy

30th International Workshop on Molecular Radiation Biology/Oncology  
17-19 June 2023 | Sørmarka, Oslo, Norway

DEGRO 2023  
22-24 June 2023 | Kassel, Germany

1st Summer School of Clinical Adaptive Radiotherapy  
26-28 June 2023 | Negrar di Valpolicella, Italy

Artificial Intelligence for imaging  
28 June - 1 July 2023 | Maastricht, The Netherlands

2nd edition of the National Conference Gynecological and Urolgical Oncology “New horizons in the multidisciplinary treatment of gynecological and urological cancers”  
7-9 September 2023 | Galați, Romania

Virtual Grand Rounds in Radiation Oncology  
9 September - 6 December 2023 | Online

Interdisciplinary head and neck brachytherapy course  
13-15 September 2023 | Krakow, Poland

19th Meet the Professor. Advanced International Breast Cancer Course (AIBC)  
21-22 September 2023 | Padova, Italy

6th Congress of South and East Europe Technology in Radiation Oncology (SEETRO)  
22-24 September 2023 | Sarajevo, Bosnia and Herzegovina

ESHO 2023  
26-29 September 2023 | Cologne, Germany

Arab African International Cancer Congress 2023 (AAICC)  
28-29 September 2023 | Cairo, Egypt

Optimizing Imaging and Dose-Response in Radiotherapies  
4-7 October 2023 | Enry, France

21st Residential Course in Modern Radiation Oncology  
9-11 October 2023 | Rome, Italy

ARTICON-2023  
14-15 October 2023 | Mumbai, India

11th Alpine Astra Medical Physics meeting  
19-22 October 2023 | Neum, Serbia

XXXII AIRO National Congress  
27-29 October 2023 | Bologna, Italy

34th Annual Congress of the Romanian Society for Radiotherapy and Medical Oncology/ 9th National Congress of the Romanian Cancer Societies Federation  
2-5 November 2023 | Cluj-Napoca, Romania

The 2nd International Multidisciplinary Anal Cancer Conference - IMMAC 2023  
9-10 November 2023 | Rome, Italy

9th Trends in Head & Neck Oncology (THNO-R)  
9-11 November 2023 | Malaga, Spain

ABCT - Advanced Breast Cancer Seventh International Consensus Conference  
9-11 November 2023 | Lisbon, Portugal

2nd MESTRO meeting  
9-11 November 2023 | Riyadh, Saudi Arabia

Online Teaching Course Particle Therapy  
9-25 November 2023 | Online

LTWSAP 2023  
17-18 November 2023 | Singapore

Billroth Memorial Laryngectomy Conference  
23-24 November 2023 | Bad Zurzach, Switzerland

INTERCRIT 2023: Cybersecurity in Radiotherapy: what to do in practice?  
23-24 November 2023 | Angers, France

LUCARRIE symposium  
25 November 2023 | Nice, France

PROSCA 2023  
26-30 November 2023 | Malaga, Spain and online

BLADDOR 2023  
1-2 December 2023 | Malaga, Spain and online

FLASH Radiotherapy and Particle Therapy (FAPT 2023)  
5-7 December 2023 | Toronto, Canada